Today, Zixin Pharmaceutical, Shuangcheng Pharmaceutical and many other individual stocks rose and stopped!

【Pharmaceutical Network Pharmaceutical Stock Market】On September 27, the ChiNext index rose more than 1%
intraday.

As of 10:09, the Shanghai Composite Index reported 3062.
65 points, up 0.
37%, with a turnover of 96.
426 billion yuan; the Shenzhen Composite Index reported 11024.
57 points, up 0.
57%, with a turnover of 128.
185 billion yuan, and the total turnover of the two cities was 224.
612 billion yuan
.

From the disk point of view, the pharmaceutical biology, communications, electronics and other sectors rose in the front
.

Among them, in terms of pharmaceutical stocks, as of 10:05, Zixin Pharmaceutical, Shuangcheng Pharmaceutical, Longjin Pharmaceutical and other individual stocks rose and stopped, and Yaokang Biological, Tebao Bio and so on rose in the front
.

In addition, Zhongsheng Pharmaceutical, Jingjing Pharmaceutical, Dali Pharmaceutical, Shouxian Valley, etc.
are also continuing to rise
.

Specifically, at 9:58, Zixin Pharmaceutical rose and fell intraday, at 2.
4 yuan, and the current sealed single 524861 hand, equivalent to 126 million yuan
.

As of now, the transaction is 40.
2453 million yuan, and the turnover rate is 1.
37%.


It is understood that Zixin Pharmaceutical has risen and stopped 7 times in
the past year.

Industry analysts believe that this is mainly affected by the rise and strengthening of the traditional Chinese medicine sector
.

The main business of Zixin Pharmaceutical is the proprietary Chinese medicine industry, ginseng industry and other industries
.

Its ginseng products are divided into roughed products and deep-processed products
.

The company has obtained 4 series of ginseng food production licenses, involving products including beverages, confectionery products, preserves, tea-containing products and substitute tea
.

In addition, on May 15, 2020, the interactive platform showed that its disinfectant products have begun to be produced and sold
.

The industry expects that Zixin Pharmaceutical will usher in an outbreak of opportunities
after the rise and fall.

At 9:26, Shuangcheng Pharmaceutical opened up and down, at 5.
35 yuan, and the current sealed order was 95495 lots, equivalent to 51.
09 million yuan
.

As of now, the transaction is 35.
1574 million yuan, and the turnover rate is 1.
61%.


It is understood that since the beginning of this year, Shuangcheng Pharmaceutical has also been up and down
many times.

On August 8, Shuangcheng Pharmaceutical ushered in a rise and stop, as of 10:50 on the same day, the stock price closed at 5.
3 yuan, up 9.
96%, the turnover was 135 million yuan, and the turnover rate was 6.
37%; On April 29, Shuangcheng Pharmaceutical opened at 6.
26 yuan, as of 09:34, the stock rose 10.
02% to 6.
26 yuan, sealing the rise and stopping the board.
.
.
According to the data, the main business of Shuangcheng Pharmaceutical is the research and development, production and sales
of chemically synthesized peptide drugs.

The main products include thymus faxin for injection of Kitai (product name), bivalirudin for injection, levocaniptine for injection, clindamycin hydrochloride for injection, motidine for injection, somatostatin for injection, and chuanqiazine
phosphate for injection.

At 10 o'clock, Longjin Pharmaceutical rose and stopped intraday, at 9.
49 yuan, and the current single 236594 hand, equivalent to 225 million yuan
.

Up to now, the transaction is 60.
0158 million yuan, and the turnover rate is 1.
67%.


It is worth mentioning that the stock has risen and stopped 24 times in
the past year.

According to the data, Longjin Pharmaceutical is a pharmaceutical company
engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs.

The company's main products are Longjin injection of calendulain, is a high-purity Chinese medicine lyophilized powder injection, the product has the effect of activating blood stasis, through the network and analgesia, used for the treatment of cardiovascular and cerebrovascular diseases, mainly used for the treatment of stroke and its sequelae, coronary heart disease, angina
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.